These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 30847416)

  • 1. Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction.
    Connelly KA; Zhang Y; Visram A; Advani A; Batchu SN; Desjardins JF; Thai K; Gilbert RE
    JACC Basic Transl Sci; 2019 Feb; 4(1):27-37. PubMed ID: 30847416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
    De Lorenzi AB; Kaplinsky E; Zambrano MR; Chaume LT; Rosas JM
    Drugs Context; 2023; 12():. PubMed ID: 36660013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment.
    Oh J; Lee SH; Lee CJ; Kang SM
    Korean Circ J; 2021 May; 51(5):399-408. PubMed ID: 33975387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin directly improves diastolic function in human heart failure.
    Pabel S; Wagner S; Bollenberg H; Bengel P; Kovács Á; Schach C; Tirilomis P; Mustroph J; Renner A; Gummert J; Fischer T; Van Linthout S; Tschöpe C; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Hamdani N; Sossalla S
    Eur J Heart Fail; 2018 Dec; 20(12):1690-1700. PubMed ID: 30328645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular diastolic and systolic dyssynchrony and dysfunction in heart failure with preserved ejection fraction and a narrow QRS complex.
    Liu S; Guan Z; Jin X; Meng P; Wang Y; Zheng X; Jia D; Ma C; Yang J
    Int J Med Sci; 2018; 15(2):108-114. PubMed ID: 29333094
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 8. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes.
    Iborra-Egea O; Santiago-Vacas E; Yurista SR; Lupón J; Packer M; Heymans S; Zannad F; Butler J; Pascual-Figal D; Lax A; Núñez J; de Boer RA; Bayés-Genís A
    JACC Basic Transl Sci; 2019 Nov; 4(7):831-840. PubMed ID: 31998851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
    Santos AB; Roca GQ; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Fang JC; Zile MR; Pitt B; Solomon SD; Shah AM
    Circ Heart Fail; 2016 Apr; 9(4):e002763. PubMed ID: 27056882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy.
    Gori M; D'Elia E; Sciatti E; Senni M
    Card Fail Rev; 2022 Jan; 8():e26. PubMed ID: 35865457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction.
    Packer M
    J Card Fail; 2019 Dec; 25(12):986-1003. PubMed ID: 31541742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction.
    Hage C; Bjerre M; Frystyk J; Gu HF; Brismar K; Donal E; Daubert JC; Linde C; Lund LH
    Am J Cardiol; 2018 Jun; 121(12):1558-1566. PubMed ID: 29622288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction - The New Frontier.
    Aguiar-Neves I; Santos-Ferreira D; Fontes-Carvalho R
    Rev Cardiovasc Med; 2023 Jan; 24(1):1. PubMed ID: 39076855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review.
    Keller DM; Ahmed N; Tariq H; Walgamage M; Walgamage T; Mohammed A; Chou JT; Kałużna-Oleksy M; Lesiak M; Straburzyńska-Migaj E
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart Failure with Preserved Ejection Fraction - Concept, Pathophysiology, Diagnosis and Challenges for Treatment.
    Miljkovik LV; Spiroska V
    Open Access Maced J Med Sci; 2015 Sep; 3(3):521-7. PubMed ID: 27275281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered spatial distribution of the diastolic left ventricular pressure difference in heart failure.
    Iwano H; Kamimura D; Fox E; Hall M; Vlachos P; Little WC
    J Am Soc Echocardiogr; 2015 May; 28(5):597-605.e1. PubMed ID: 25691001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
    Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Barron B; Mayoux E; Rector RS; Whaley-Connell A; DeMarco VG
    Cardiovasc Diabetol; 2017 Jan; 16(1):9. PubMed ID: 28086951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Predictors of Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Preclinical Left Ventricular Diastolic Dysfunction.
    Zhang L; Liebelt JJ; Madan N; Shan J; Taub CC
    Am J Cardiol; 2017 Jun; 119(11):1815-1820. PubMed ID: 28450040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.